Abstract 1438P
Background
SPOTLIGHT and GLOW showed improved progression-free and overall survival (PFS, OS) with 1L zolbetuximab + chemotherapy vs placebo + chemotherapy in pts with CLDN18.2+, HER2–, LA unresectable or mG/GEJ adenocarcinoma at interim and updated analyses. Here we present the pooled final OS analysis.
Methods
Pts were randomly assigned 1:1 to zolbetuximab IV (800 mg/m2 cycle 1 day 1, then 600 mg/m2 every 3 weeks) + chemotherapy (SPOTLIGHT, mFOLFOX6: folinic acid, fluorouracil, oxaliplatin IV every 2 weeks; GLOW, CAPOX: capecitabine twice daily days 1–14, oxaliplatin IV every 3 weeks) or placebo + chemotherapy for four 42-day cycles (SPOTLIGHT) or eight 21-day cycles (GLOW). Pts continued zolbetuximab/placebo, + capecitabine (GLOW) or + folinic acid + fluorouracil (SPOTLIGHT) per investigator decision, until progressive disease (PD) or discontinuation criteria were met. Endpoints included PFS (primary), OS (key secondary), and objective response rate (ORR)/safety (secondary).
Results
The addition of zolbetuximab continued to improve both PFS and OS at final analysis (n=1072; Table). The most common treatment-emergent adverse events (TEAEs) with zolbetuximab + chemotherapy were nausea (76.0% vs 56.2% in zolbetuximab vs placebo arms), vomiting (66.8% vs 34.2%), and decreased appetite (45.2% vs 34.7%); serious TEAEs (48.0% vs 48.4%), grade ≥3 TEAEs (80.7% vs 74.8%), and drug-related TEAEs leading to death (2.1% vs 2.3%) were similar in both arms. Table: 1438P
| Zolbetuximab + chemotherapy | Placebo + chemotherapy | |
| PFS | ||
| Median, mo (95% CI) | 9.2 (8.4–10.4) | 8.2 (7.6–8.4) |
| HRa (95% CI); 1-sided P value | 0.71 (0.61–0.83); ConclusionsZolbetuximab + chemotherapy continued to demonstrate statistically significant and clinically meaningful improvement in PFS and OS vs placebo + chemotherapy, with no new safety signals—supporting zolbetuximab + chemotherapy as a new standard for 1L treatment of pts with CLDN18.2+, HER2–, LA unresectable or mG/GEJ adenocarcinoma. Clinical trial identificationNCT03504397; NCT03653507. Editorial acknowledgementMedical writing support was provided by Ann Ferguson, PhD, of Oxford PharmaGenesis Inc. Legal entity responsible for the studyAstellas Pharma Inc. FundingAstellas Pharma Inc. DisclosureY. Kang: Financial Interests, Personal, Advisory Board: ALX Oncology, Zymeworks, Amgen, Novartis, Macrogenics, Daehwa, Blueprint, Surface Oncology, BMS, Merck, Roche, Liscure. M.A. Shah: Financial Interests, Personal, Funding: Merck, Bristol Myers Squibb, Oncolys Biopharma. K. Shitara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Takeda, Ono Pharmaceutical, MSD, Novartis, Daiichi Sankyo, Amgen, Guardant Health Japan Corp, Astellas Pharma Inc., Astellas, Bayer, AstraZeneca, Zymeworks Biopharmaceuticals Inc., ALX Oncology Inc.; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Janssen, AstraZeneca, Eli Lilly, Astellas, Ono Pharmaceutical; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Eisai, Amgen, PRA Health Sciences. J.A. Ajani: Financial Interests, Personal, Advisory Board: BMS, Gilead, Astellas, AZ, Jazz, KirinKyowa, Servier, BeiGene, Daiichi Sankyo; Financial Interests, Institutional, Coordinating PI, My institution receives funding: BMS; Financial Interests, Institutional, Coordinating PI: Merck, Jazz, Astellas, DeltaFly, Gilead, Roche. F. Lordick: Financial Interests, Personal, Advisory Board: Amgen, Astellas, BMS, Bayer, BeiGene, BioNTech, Eli Lilly, Elsevier, MSD, Novartis, Roche, Daiichi Sankyo, PAGE; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Eli Lilly, Imedex, Incyte, MSD, MedUpdate, Medscape, Merck Serono, Roche, Servier, StreamedUp!, Daiichi Sankyo, Novartis, Art Tempi; Financial Interests, Personal, Writing Engagement: Deutscher Ärzteverlag, Iomedico, Springer-Nature; Financial Interests, Institutional, Research Grant: BMS, Gilead. E. Van Cutsem: Financial Interests, Personal, Advisory Board: AbbVie, Agenus, ALX, Arcus Biosciences, Astellas, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, Elmedix, Eisai, GSK, Hoopika Biotech, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Seattle Genetics, Servier, Simcere, Takeda, Taiho, Terumo; Financial Interests, Personal, Invited Speaker: Amgen, Pfizer. S.J. Klempner: Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Merck, Bristol Myers Squibb, Astellas, Daiichi Sankyo; Financial Interests, Personal, Advisory Board, One Time Advisory Board: Natera; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x 1, 2023: Mersana; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x 1: Sanofi-Aventis; Financial Interests, Personal, Advisory Board, Stomach Cancer consulting, ended in 1/2024: Novartis; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x1 in 1/2024: AstraZeneca; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x1 in 3/2024: I-Mab Therapeutics; Financial Interests, Personal, Advisory Board, Stomach cancer consulting, <$1,500 USD in 2023: Taiho Oncology; Financial Interests, Personal, Advisory Board, Stomach cancer advisory board x1, planned for 6/2024: Eisai; Financial Interests, Personal, Stocks/Shares, Stock Ownership, ended in 6/2022: Turning Point Therapeutics; Financial Interests, Personal, Stocks/Shares, Early investor, company is not public: MBrace; Financial Interests, Institutional, Coordinating PI, National PI for trial: Leap Therapeutics; Financial Interests, Personal and Institutional, Local PI, Local PI for trial, also served on advisory board as noted above: Astellas; Financial Interests, Institutional, Local PI, Ended in 2022: Macrogenics; Financial Interests, Institutional, Coordinating PI, Trial PI, ended in 2023: Silverback; Financial Interests, Institutional, Local PI, Site PI for phase III trials: Arcus; Financial Interests, Personal and Institutional, Local PI, Site PI for trial, as disclosed above was a one-time advisory board participant, <$5,000 USD: I-Mab; Non-Financial Interests, Advisory Role, Medical-Scientific Advisory Board Member: Debbies Dream Foundation; Non-Financial Interests, Advisory Role, Member of Scientific Advisory Board: Hope for Stomach Cancer; Non-Financial Interests, Other, Member of Gastric and Esophageal NCCN Guideline Committees: NCCN; Other, Participant in gastroesophageal CME activities, compensated, last in 3/2024: Research to Practice. K. Yamaguchi: Financial Interests, Personal, Expert Testimony: Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K. Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd. Bristol Myers Squibb K.K., Takeda Pharmaceutical Co., Ltd. T. Nakajima, Y.J. Cao, R. Li, R.R. Pophale: Financial Interests, Personal, Full or part-time Employment: Astellas. R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD, Hutchison Pharm; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astalas, Merck, Junshi, Innovent, Keymed Biosience. All other authors have declared no conflicts of interest. Resources from the same session1505P - Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)Presenter: Anton Lahusen Session: Poster session 18 1506P - ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patientsPresenter: Tingting You Session: Poster session 18 1507P - Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancerPresenter: Marie-Edith Bonneterre Session: Poster session 18 1509P - Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypesPresenter: Laura Gutierrez Sainz Session: Poster session 18 1510P - Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapyPresenter: Sai Surendran Session: Poster session 18 1511P - The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapyPresenter: Steffen Ormanns Session: Poster session 18 1512P - The role of pancreaticoduodenectomy for octogenarians with pancreatic cancerPresenter: Keita Sonoda Session: Poster session 18 1513P - Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)Presenter: Omali Pitiyarachchi Session: Poster session 18 1514P - A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancerPresenter: Jae Young Lee Session: Poster session 18 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|